SVB Wealth LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 48.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,231 shares of the company’s stock after selling 13,154 shares during the period. SVB Wealth LLC’s holdings in Zoetis were worth $994,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. BlackRock Inc. boosted its stake in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. State Street Corp increased its stake in shares of Zoetis by 1.8% in the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after acquiring an additional 343,322 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Zoetis by 7.3% in the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after acquiring an additional 327,313 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Zoetis by 5.8% during the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after acquiring an additional 319,709 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Zoetis by 7.7% during the 2nd quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock worth $305,559,000 after acquiring an additional 303,395 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on ZTS shares. Piper Sandler lowered their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. UBS Group raised their price objective on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 27th. Zacks Research raised shares of Zoetis from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. William Blair lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Finally, TD Cowen decreased their target price on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $101.25.
View Our Latest Report on Zoetis
Zoetis Price Performance
NYSE:ZTS opened at $83.65 on Monday. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $132.49. The stock’s fifty day moving average is $76.28 and its two-hundred day moving average is $91.56. The company has a market capitalization of $33.99 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.21 and a beta of 0.67. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.70 EPS. Equities analysts expect that Zoetis Inc. will post 6.29 EPS for the current year.
Zoetis Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is 36.05%.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Read More
- Five stocks we like better than Zoetis
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
